No quarterly revenue total was found in Immunic, Inc.'s SEC filings.
Immunic, Inc. (IMUX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$31.2 million. As of Jun 30, 2026 it held $155.1 million in cash and investments and $567,000 in total debt.
Revenue
—
Net income
$-34.10M
-27.1% vs year-ago quarter
Operating cash flow
$-31.00M
-26.0% vs year-ago quarter
Free cash flow
$-31.25M
-26.8% vs year-ago quarter
EPS
$-0.80
+60.6% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
13.64M
-86.2% vs year-ago quarter
Net cash
$154.53M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMUX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, United States
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1280776
- Former names
- VITAL THERAPIES INC (until Apr 10, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$35.3M | -$33.2M | -$23.3M | -$26.0M | -$27.1M |
| Net income | -$34.1M | -$32.6M | -$19.3M | -$25.6M | -$26.8M |
| Diluted EPS | -$0.80 | -$1.08 | -$0.10 | -$0.13 | -$2.03 |
| Operating cash flow | -$31.0M | -$17.3M | -$19.3M | -$20.1M | -$24.6M |
| Free cash flow | -$31.2M | -$17.3M | -$19.3M | -$20.2M | -$24.6M |
| Total assets | $159.2M | $189.7M | $24.1M | $40.7M | $61.4M |
| Total liabilities | $31.6M | $38.5M | $30.7M | $30.2M | $27.5M |
| Stockholders' equity | $127.6M | $151.2M | -$6.7M | $10.5M | $33.9M |
| Cash and investments | $155.1M | $186.6M | $15.5M | $35.1M | $55.3M |
| Total debt | $567,000 | $421,000 | $577,000 | $792,000 | $979,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Aug 11, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 14, 2026 | Jul 14, 2026 |
All 832 Immunic, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.